

Antonios Douros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5269930/publications.pdf>

Version: 2024-02-01

62
papers

1,446
citations

304602

22
h-index

360920

35
g-index

64
all docs

64
docs citations

64
times ranked

2152
citing authors

#	ARTICLE	IF	CITATIONS
1	Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention Among Patients With Hypertension in the United Kingdom. <i>American Journal of Hypertension</i> , 2022, 35, 42-53.	1.0	11
2	Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 994-1009.	1.1	2
3	Effectiveness and safety of direct oral anticoagulants with antiplatelet agents in patients with venous thromboembolism: A multi-database cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12643.	1.0	3
4	Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 1248-1257.	2.3	8
5	Relative effectiveness of medications for opioid-related disorders: A systematic review and network meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2022, 17, e0266142.	1.1	13
6	5 α -reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3771-3781.	1.1	1
7	Response to: <scp>Real-World</scp> Data on the Risk of Ventricular Arrhythmias with Sulphonamides. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 203-203.	2.3	0
8	Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Venous Thromboembolism in Patients with Type 2 Diabetes: A Cohort Study. <i>American Journal of Medicine</i> , 2021, 134, 606-613.e6.	0.6	6
9	Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection—A pharmacovigilance analysis. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00707.	1.1	7
10	Global <scp>COVID-19</scp> pandemic and reporting behavior —An analysis of the Food and Drug Administration adverse events reporting system. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 707-715.	0.9	12
11	Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta-analysis of observational studies. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3649-3658.	1.1	20
12	Infectious Disease Burden and the Risk of Alzheimer's Disease: A Population-Based Study. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 329-338.	1.2	13
13	Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 697-705.	1.5	8
14	Effectiveness and safety of direct oral anticoagulants in patients with cancer associated venous thromboembolism. <i>Thrombosis Research</i> , 2021, 202, 128-133.	0.8	9
15	Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study. <i>BMC Health Services Research</i> , 2021, 21, 758.	0.9	8
16	The modifying effects of adiposity on the cardiovascular safety of sulphonylureas. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2502-2512.	2.2	0
17	Investigating Potential Drug-Drug Interactions from Greek e-Prescription Data. <i>Current Drug Safety</i> , 2021, 16, .	0.3	2
18	Control of blood pressure in older patients with heart failure and the risk of mortality: a population-based prospective cohort study. <i>Age and Ageing</i> , 2021, 50, 1173-1181.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 254-262.	2.2	6
20	Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis. <i>Annals of Internal Medicine</i> , 2020, 173, 417-425.	2.0	97
21	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. <i>Diabetes Care</i> , 2020, 43, 2444-2452.	4.3	26
22	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. <i>BMJ, The</i> , 2020, 370, m3342.	3.0	70
23	Direct oral anticoagulants and oesophageal disorders: a pharmacovigilance analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1045-1047.	0.8	1
24	Sodium-glucose cotransporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1648-1658.	2.2	13
25	Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study. <i>BMC Geriatrics</i> , 2020, 20, 22.	1.1	19
26	Author response: Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study. <i>Neurology</i> , 2020, 95, 232-232.	1.5	1
27	Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2378-2389.	1.1	31
28	Degree of serotonin reuptake inhibition of antidepressants and ischemic risk. <i>Neurology</i> , 2019, 93, e1010-e1020.	1.5	22
29	Opioids and the Risk of Infection: A Critical Appraisal of the Pharmacologic and Clinical Evidence. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 565-575.	1.5	26
30	Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies. <i>Drug Safety</i> , 2019, 42, 1135-1148.	1.4	23
31	Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1496-1503.	4.3	43
32	RE: Metformin Use and Gastric Cancer Risk in Diabetic Patients After Helicobacter pylori Eradication. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1107-1108.	3.0	1
33	Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study. <i>European Heart Journal</i> , 2019, 40, 2021-2028.	1.0	54
34	Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2019, 42, e150-e152.	4.3	22
35	Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. <i>Journal of Hypertension</i> , 2019, 37, 1950-1958.	0.3	46
36	What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®. <i>Journal of General Internal Medicine</i> , 2019, 34, 502-503.	1.3	19

#	ARTICLE	IF	CITATIONS
37	Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019, 132, 191-199.e12.	0.6	28
38	Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1105-1113.	1.2	36
39	Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 360, k872.	2.4	89
40	Risk of Intracranial Hemorrhage Associated with the Use of Antidepressants Inhibiting Serotonin Reuptake: A Systematic Review. <i>CNS Drugs</i> , 2018, 32, 321-334.	2.7	27
41	Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. <i>Epidemiology</i> , 2018, 29, 904-912.	1.2	14
42	Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 363, k4880.	2.4	33
43	FOO29HYPERTENSION CONTROL AND MORTALITY IN A COHORT OF OLDER ADULTS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i30-i31.	0.4	0
44	Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. <i>Diabetes Care</i> , 2018, 41, 2330-2338.	4.3	32
45	Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. <i>BMJ: British Medical Journal</i> , 2018, 362, k2693.	2.4	81
46	Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study. <i>Current Vascular Pharmacology</i> , 2018, 16, 197-203.	0.8	7
47	Drug-induced kidney injury: A large case series from the Berlin Case-Control Surveillance Study. <i>Clinical Nephrology</i> , 2018, 89, 18-26.	0.4	14
48	Risks Associated With Using Sulfonylureas As A Treatment For Type 2 Diabetes. , 2018, , .		0
49	Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1149-1155.	0.9	3
50	Patterns of long-term use of non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation: Quebec observational study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1546-1554.	0.9	18
51	Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. <i>Diabetes Care</i> , 2017, 40, 1506-1513.	4.3	64
52	Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 114.	1.8	33
53	Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016, 41, 718-721.	0.7	26
54	Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 839-848.	1.1	17

#	ARTICLE	IF	CITATIONS
55	Safety issues and drug-drug interactions with commonly used quinolones. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 25-39.	1.5	40
56	Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. British Journal of Clinical Pharmacology, 2015, 79, 988-999.	1.1	62
57	Estimating kidney function and use of oral antidiabetic drugs in elderly. Fundamental and Clinical Pharmacology, 2015, 29, 321-328.	1.0	17
58	Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1849-1859.	1.5	68
59	Flupirtine-induced liver injury—Seven cases from the Berlin Case-control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. European Journal of Clinical Pharmacology, 2014, 70, 453-459.	0.8	27
60	Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. Thrombosis and Haemostasis, 2014, 112, 419-420.	1.8	18
61	Ramipril-Induced Liver Injury: Case Report and Review of the Literature. American Journal of Hypertension, 2013, 26, 1070-1075.	1.0	17
62	Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases. Alimentary Pharmacology and Therapeutics, 2013, 38, 825-834.	1.9	25